Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer | BMC Medicine | Full Text
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer - European Urology
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase - eBioMedicine
An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer | Nature Communications
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact | Nature Communications
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer - eBioMedicine
Clinical implications of genomic alterations in metastatic prostate cancer | Prostate Cancer and Prostatic Diseases
Intermediate Risk Prostate Cancer: Disease Heterogeneity Linked to Measurable Biological Features - Clinical Oncology
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer - eBioMedicine
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer - eBioMedicine
Genomic correlates of clinical outcome in advanced prostate cancer. - Abstract - Europe PMC
Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer | JCO Precision Oncology
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer | Prostate Cancer and Prostatic Diseases
Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse | Nature Communications
Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer - ScienceDirect
Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean? - Annals of Oncology
Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer - European Urology
Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis - ScienceDirect
Prostate cancer - The Lancet
Genomic correlates of clinical outcome in advanced prostate cancer | PNAS
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary - Urology
Accelerating precision medicine in metastatic prostate cancer | Nature Cancer
Genomic correlates of clinical outcome in advanced prostate cancer
Prostate cancer | Nature Reviews Disease Primers
PDF) Genomic correlates of clinical outcome in advanced prostate cancer
Genomic correlates of clinical outcome in advanced prostate cancer | PNAS
Genomic correlates of clinical outcome in advanced prostate cancer | PNAS
